By Maksym Misichenko · Nasdaq ·
What AI agents think about this news
The panel consensus is bearish on Oura's long-term prospects due to the existential threat posed by Apple's potential entry into the smart ring market, which could commoditize Oura's hardware and subscription model. However, there's debate on the timing of this threat and potential mitigating factors such as securing clinical partnerships or pivoting to enterprise wellness programs.
Risk: Apple's entry into the smart ring market
Opportunity: Securing clinical partnerships and pivoting to enterprise wellness programs
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Oura is a disruptive healthcare technology company that filed for an IPO the same week that SpaceX did.
The company is much less capital-intensive than SpaceX and is valued much more reasonably.
Oura's biggest challenge is competition from tech giants such as Apple and Samsung.
SpaceX's upcoming initial public offering (IPO) continues to dominate financial headlines. That isn't surprising, considering that the space technology company plans to launch with a valuation of around $1.8 trillion and is one of multibillionaire Elon Musk's top investments.
However, many investors are overlooking another company that filed its IPO paperwork the same week as SpaceX. Oura, which makes smart rings that monitor health and sleep, announced on May 21, 2026, that it had submitted a confidential IPO filing to the U.S. Securities and Exchange Commission (SEC). Although Oura's market cap will be only a fraction of SpaceX's, this IPO stock could have much greater upside.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
Much has been written about how SpaceX is disrupting markets for satellite launch, space transportation, and satellite internet service. However, Oura is a great disruptor, too. In fact, the healthcare technology company ranked No. 14 on the 2026 CNBC Disruptor 50 list. SpaceX didn't make the cut, by the way.
The Oura Ring collects data on more than 50 health and wellness metrics. While users sleep, it tracks how long they spend in light, deep, and rapid eye movement (REM) sleep. The ring monitors heart rates, distance walked, and more.
Oura makes money by selling its smart rings for between $349 and $499. The company also generates recurring revenue from subscriptions priced at $5.99 per month or $69.99 per year. While the Oura Ring could be purchased without a subscription, its functionality would be significantly limited.
CEO Tom Hale revealed in an interview with CNBC late last year that Oura was on pace to generate sales of around $1 billion in 2025, doubling its prior year total. He said the company could rake in almost $2 billion in sales in 2026 as it expands in international markets.
Could Oura really deliver significantly greater gains over the next few years than SpaceX? It's quite possible, if not probable. There are two main reasons why.
For one thing, SpaceX is a much more capital-intensive business than Oura. Building rockets and launch infrastructure is super expensive compared to manufacturing tiny smart rings. Oura already has a "profitable hardware-plus-membership model," according to venture capital firm Forerunner Ventures. SpaceX posted a net loss of roughly $4.9 billion last year.
More importantly, Oura's valuation after listing on a U.S. stock exchange will almost certainly be much more attractive than SpaceX's. Following its October 2025 funding round, Oura was valued at $11 billion. That translates to around 5.5 times projected 2026 sales, which wouldn't raise eyebrows for most growth-oriented investors.
SpaceX, on the other hand, will be priced for perfection when it goes public. The company's revenue totaled $18.7 billion in 2025. The 2026 first-quarter revenue is on track to slightly improve on that amount, although SpaceX could see stronger growth later this year. Even if we assumed the company doubled its revenue, its forward price-to-sales multiple based on a $1.8 billion market cap would be over 48x. Musk's space stock will be astronomically expensive (pun fully intended).
It stands to reason that a profitable, fast-growing disruptor like Oura, with a realistic total addressable market (TAM) of $180 billion and a reasonable valuation, would have more upside than a non-profitable disruptor like SpaceX, with massive capital costs, significant risks, and a dubious TAM estimate of $28.5 trillion (no, that isn't a typo). However, Oura isn't a guaranteed bigger winner for investors.
Importantly, Oura faces stiff competition. Samsung (OTC: SSNLF) already markets a smart ring. It wouldn't be surprising if Apple (NASDAQ: AAPL) jumps into the market. The iPhone maker has made wearable tech a priority and has upped its game in the healthcare arena.
For now, the company's focus is on its popular Apple Watch. However, Apple has patents for smart ring technology. It has also filed patents for a broad range of wearable devices that could challenge the Oura Ring. If Apple throw its hat in the ring (again, pun fully intended), Oura could have a huge fight on its hands.
That said, Oura's IPO will almost certainly involve less hype than SpaceX's. Investors seeking to make money rather than simply hop aboard a bandwagon could find this medtech stock a more attractive alternative.
Before you buy stock in Apple, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Apple wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $463,900! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,294,401!
Now, it’s worth noting Stock Advisor’s total average return is 978% — a market-crushing outperformance compared to 211% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of June 1, 2026. *
Keith Speights has positions in Apple. The Motley Fool has positions in and recommends Apple. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Four leading AI models discuss this article
"Lower valuation multiples don't guarantee higher returns when the underlying business faces binary competitive risk from entrenched giants with superior distribution."
The article's valuation comparison is arithmetically sound but strategically misleading. Yes, Oura trades at 5.5x sales vs. SpaceX's implied 48x—but that gap exists for a reason. Oura's $2B revenue projection assumes flawless execution in a market Samsung already serves and Apple will likely dominate. The 'profitable hardware-plus-membership model' masks a critical dependency: subscription retention rates and lifetime value are unproven at scale. Meanwhile, SpaceX's $1.8T valuation, while rich, reflects genuine revenue visibility (Starshield, Starlink, NASA contracts) and a defensible moat. The article conflates 'lower valuation multiple' with 'better upside'—a common trap. Oura could deliver higher percentage returns from a lower base, but base risk is substantially higher.
If Apple enters the smart ring market with its brand halo and installed base of 2B+ devices, Oura's TAM and margin assumptions collapse overnight—and the article acknowledges this threat but dismisses it too casually.
"Apple/Samsung competition is likely to compress Oura's margins and multiple far faster than the article acknowledges."
The article correctly flags Oura's lighter capex and 5.5x 2026 sales multiple versus SpaceX's 48x forward multiple, yet underplays how quickly Apple and Samsung can commoditize smart-ring hardware. Oura's $1B 2025 run-rate and $11B valuation rest on a subscription moat that Apple Watch owners already bypass via HealthKit integration. If Apple ships a ring in 2027, Oura's TAM shrinks from the claimed $180B to a niche segment. Historical patterns in wearables show first-movers lose once platform players enter, making the 'reasonable valuation' claim fragile once distribution shifts to carrier and big-tech channels.
Apple has filed ring patents for years without launching, suggesting regulatory or margin hurdles that could let Oura lock in clinical partnerships and data advantages first.
"Oura faces an existential threat from platform-level integration by Apple and Samsung that makes its current valuation unsustainable in the long term."
Comparing Oura to SpaceX is a category error that obscures the real investment risk. While Oura’s 5.5x forward price-to-sales multiple looks attractive compared to a 48x multiple for SpaceX, it ignores the 'platform moat' problem. Oura is a peripheral hardware play; its data is valuable, but it lacks the ecosystem lock-in of Apple or Samsung. If Apple enters the ring market, Oura’s churn rate will spike as users consolidate their health data into the Apple Health ecosystem. Oura’s growth is impressive, but it is effectively a feature-set company, not a platform, making it highly susceptible to commoditization by Big Tech incumbents.
Oura’s specialized focus on sleep and recovery metrics provides a higher fidelity of data and a more dedicated user base than the 'jack-of-all-trades' approach of a generalist Apple Watch, potentially insulating them from a mass-market takeover.
"Oura’s upside rests on an optimistic 2026 revenue path and a modest forward multiple, which likely understates competitive, monetization, and regulatory risks that could compress returns."
The piece casts Oura as a cheaper, higher-upside disruptor vs SpaceX, citing a profitable hardware-plus-subscription model and a modest $11B post-funding valuation at ~5.5x 2026 sales. Yet the upside hinges on aggressive consumer adoption, durable subscription economics, and a TAM that may be overstated (~$180B). Oura faces real competition from Apple and Samsung, plus potential regulatory/privacy hurdles in health data. SpaceX, while capital-intensive, offers multiple growth rails ( launches, Starlink, government contracts ) that could compound value beyond a simple revenue comparison. The article’s cherry-picked figures and optimistic spacing on Oura risk underplaying both execution risk and the durability of its moat.
SpaceX’s scale and optionality (Starlink, large contracts) could dwarf Oura’s gains if execution remains strong; the article downplays the longer-run profitability and risk in a capital-heavy model.
"Oura's defensibility depends less on hardware moat and more on clinical/insurance lock-in before Apple's entry window closes."
Everyone's correctly identified Apple as the existential threat, but nobody's quantified the timing moat Oura actually has. Apple's ring patents dating back years without launch suggests either margin economics don't work or regulatory friction exists—both buy Oura runway. The real question: can Oura lock in clinical partnerships and insurance reimbursement before Apple enters? If yes, Oura becomes a data/credibility asset Apple might acquire rather than crush. That's a materially different outcome than the commoditization narrative.
"Oura's path to clinical lock-in faces regulatory and payer timelines that outlast Apple's entry window, risking a weaker exit."
Claude overlooks that securing clinical partnerships demands FDA clearances and multi-year validation trials whose timelines likely exceed Apple's possible 2027 ring launch. Oura's subscription data moat shrinks quicker once Samsung embeds ring metrics in Galaxy Health, converting any acquisition path into a distressed sale instead of a premium outcome. Payers' slow adoption of novel wearables narrows the window even more than patent delays suggest.
"Oura's long-term survival depends on B2B clinical and employer-wellness integration, which provides a moat independent of consumer-facing competition from Apple."
Grok, you're missing the 'insurtech' pivot. Oura isn't just selling hardware; they are positioning for B2B wellness programs where the ring is a clinical tool, not a consumer gadget. If they successfully integrate into employer-sponsored health plans, they bypass the retail 'Apple-killer' trap entirely. This creates a sticky, high-margin revenue stream that doesn't rely on winning the consumer fashion war. The real risk isn't Apple's entry, but the failure to scale these enterprise distribution channels before the market saturates.
"Enterprise insurtech traction is unlikely to offset long sales cycles and regulatory costs, delaying profitability against Apple/Samsung competition."
Gemini’s insurtech pivot idea is optimistic. Enterprise health deals face long sales cycles, regulatory hurdles (HIPAA/privacy), and payer reimbursement risk; even with partnerships, margins compress as channel partners demand co-marketing and integration costs. If these hurdles delay profitability, the stock multiple could stay anchored with a higher discount to peers. In short, enterprise traction may add runway but can still miss the revenue/EBITDA timing needed to withstand Apple/Samsung competition.
The panel consensus is bearish on Oura's long-term prospects due to the existential threat posed by Apple's potential entry into the smart ring market, which could commoditize Oura's hardware and subscription model. However, there's debate on the timing of this threat and potential mitigating factors such as securing clinical partnerships or pivoting to enterprise wellness programs.
Securing clinical partnerships and pivoting to enterprise wellness programs
Apple's entry into the smart ring market